Roche says REMDACTA trial misses in severe COVID-19 pneumonia

11 March 2021

Roche (ROG: SIX) today revealed that the global Phase III randomized, double-blind, multicenter REMDACTA study of Actemra/RoActemra (tocilizumab) plus Veklury (remdesivir), versus placebo plus Veklury, did not meet its primary endpoint.

This was measured by improved time to hospital discharge up to day 28 in patients with severe COVID-19 pneumonia receiving standard of care. No new safety signals were identified for Actemra/RoActemra in the REMDACTA trial, the Swiss pharma giant said.

The study was conducted in collaboration with Gilead Sciences (Nasdaq: GILD), which markets Veklury, anti-viral agent that generated $1.9 billion sales in the fourth quarter of 2020. Veklury in October last year became the first drug to gain full US Food and Drug Administration approval for COVID-19. It was previously cleared under the emergency use system.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK